FDA says Naveh Pharma and Bigdam sell unapproved saline drug products in the U.S. and have no quality unit.
What happened
FDA reviewed the companies' websites (navehpharma.com, u-better.com) and an Amazon storefront in March 2026 and found the saline products promoted to treat RSV bronchiolitis and lung disease. FDA also reviewed records the firm sent in response to an April 28, 2025 request for records under section 704(a)(4) of the FD&C Act for the Netanya, Israel facility. Those records stated the firm has no quality unit overseeing manufacture and release of drug products shipped to the United States.
What FDA found
The saline products are promoted to treat RSV bronchiolitis and lung disease, which makes them drugs, but they have no FDA-approved application.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)The products are not generally recognized as safe and effective for the uses claimed on the labeling, so they are 'new drugs' that cannot be sold without approval.
FD&C Act section 201(p), 21 U.S.C. 321(p)The firm has no quality unit with the responsibility and authority to approve or reject components, packaging, labeling and finished drug products.
21 CFR 211.22(a)Because manufacturing controls do not meet CGMP, the drug products are adulterated.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
Within 15 working days, tell FDA in writing what steps you have taken to correct the violations, with supporting documents, and send a full assessment and plan for setting up a quality unit with real authority and resources. Send it to FDAAdvisory@fda.hhs.gov with the firm name and identifier 724669 in the subject line, or explain why more time is needed and when you will finish.
Who should pay attention
- brands and distributors that buy saline or inhalation products from this manufacturer
- U.S. retailers and Amazon sellers listing these saline products
- companies whose overseas suppliers answer FDA record requests instead of facing inspection
This is a summary. Read the original letter on fda.gov.